OvaScience Inc. (OVAS) Rating Lowered to Hold at Zacks Investment Research

OvaScience Inc. (NASDAQ:OVAS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a report on Thursday, June 22nd.

OvaScience (NASDAQ:OVAS) opened at 1.41 on Thursday. OvaScience has a 1-year low of $1.25 and a 1-year high of $7.65. The stock’s 50 day moving average is $1.41 and its 200 day moving average is $1.48. The company’s market cap is $50.32 million.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.02. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The business’s quarterly revenue was down 55.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) EPS. Equities analysts anticipate that OvaScience will post ($1.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/05/ovascience-inc-ovas-rating-lowered-to-hold-at-zacks-investment-research.html.

Large investors have recently bought and sold shares of the stock. UBS Asset Management Americas Inc. bought a new stake in OvaScience during the 1st quarter valued at $107,000. Zacks Investment Management bought a new stake in OvaScience during the 2nd quarter valued at $140,000. LMR Partners LLP bought a new stake in OvaScience during the 2nd quarter valued at $145,000. Susquehanna International Group LLP raised its holdings in OvaScience by 87.2% during the 2nd quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 52,538 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in OvaScience by 28.8% during the 2nd quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock valued at $256,000 after buying an additional 36,720 shares during the last quarter. Institutional investors own 56.28% of the company’s stock.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply